<DOC>
	<DOCNO>NCT00185172</DOCNO>
	<brief_summary>To test efficacy safety olmesartan patient essential hypertension .</brief_summary>
	<brief_title>Olmesartan Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Age : 18 ( 19 require local authority ) 75 year Males females race . Female participant must take adequate contraceptive measure ( oral contraceptive , I.U.D . ) , postmenopausal surgically sterilize Essential hypertension : sit DBP great equal 90 less 110 mmHg Written Informed Consent Mentally competent Negative pregnancy test woman childbearing age begin study Patients know severe ( World Health Organization ( WHO ) stage III , sit DBP stable great equal 110 mmHg ) , malignant secondary hypertension Patients myocardial infarction percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) within last 6 month Patients history current evidence congestive heart failure Bilateral renal artery stenosis Severe renal insufficiency ( serum creatinine great 200 micro mol/l ) Severe hepatic impairment biliary obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>